{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/62603d57c200ba0012453160?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ebe8cc563e3d811bbd2c9d8/1589546617002-fe8127d1b39ab8ac94a64885bbfaa0ae.jpeg?height=200","description":"<p>During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal antibodies to treat relapsed/refractory multiple myeloma?</p><p><br></p><p>Mateos begins by giving an overview of the bispecific antibodies, talquetamab and teclistamab. These antibodies have been investigated in combination with daratumumab in two clinical trials; Mateos provides a summary of the results of these trials, including the safety and efficacy data.</p>","author_name":"Scientific Education Support"}